Tissue Regenix Grants Share Options to CEO and EMEA Director
Why we think this is neutral
This RNS announcement is related to the grant of share options to the CEO and EMEA Business Director of Tissue Regenix Group plc. As a director dealings announcement, it does not contain any information about the company's trading performance, financial results, or other key business updates. Therefore, the sentiment is assessed as neutral, as the news is informational but does not provide any significant insights into the company's underlying performance or prospects.
Key Points
- Tissue Regenix Group plc granted restricted share units (RSUs) to CEO Daniel Lee and conditional share awards (CSAs) to EMEA Business Director Kirsten Lund
- The RSUs and CSAs are subject to continued service over a three-year period and satisfaction of performance conditions
- Following the grant, Daniel Lee holds options over 1,078,135 RSUs (1.53% of issued share capital) and Kirsten Lund holds options over 305,176 CSAs (0.43% of issued share capital)
Summary
Tissue Regenix Group plc has announced the grant of restricted share units (RSUs) to CEO Daniel Lee and conditional share awards (CSAs) to EMEA Business Director Kirsten Lund. The RSUs and CSAs are subject to continued service over a period of three years and satisfaction of customary performance conditions. Following the grant, Daniel Lee holds options over 1,078,135 RSUs representing 1.53% of the current issued share capital, and Kirsten Lund holds options over 305,176 CSAs representing 0.43% of the current issued share capital.